In April, UnitedHealth became one of the first large nationwide insurers to announce that it would cut back its participation and begin operating only in a "handful" of the ObamaCare exchanges in 2017. The company cited the unstable dynamic of the exchanges, as well its loss of $475 million in 2015 and a projected $650 million loss in 2016. In July, after losing nearly $1 billion in a year, Humana announced it will operate in only 11 states in 2017, down from 19 states in 2016. In August, Aetna announced it was reducing participation in ObamaCare by more than two-thirds after suffering a loss of more than $200 million in the second quarter of 2016 and more than $430 million since 2014.The McKinsey Center for U.S. Health System Reform, which studies the ACA and its implications, showed in an Aug. 18 analysis that the percentage of counties in the U.S. with five or more participating insurance carriers remaining in the exchanges will likely shrink from 51 percent in 2016 to 31 percent in 2017, and the number of counties having only one carrier participating will likely grow from 2 percent in 2016 to 17 percent in 2017. Pinal County in Arizona found out in August that it will have no insurance carriers participating in ObamaCare exchanges in 2017.
This massive insurer exodus from Obamacare markets not only creates a shrinking pool of competition and narrower networks, but could also be setting the stage for something far more devastating: the inevitable push for a single-payer or public option to either be added to, or replace, ObamaCare.
In an Aug. 2 Journal of the American Medical Association article, President Obama, despite the overwhelming evidence that heavy-handed government control has not worked to make quality healthcare more affordable, called for adding a public option; more tax dollars to prop up the exchanges; more government bureaucrats and politicians making decisions on how healthcare is delivered to our nation's citizens; and pharmaceutical price controls, which would destroy research and development and deny patients access to promising new therapies.